Biotech Values

[flatlander_60048]

Not very satisfying to have no idea what the settlement terms were. Initially NVS threatened treble damages on any ill gotten gains Teva may have received by launching at risk. All mention of the litigation ceased a couple of years ago.

I believe Lotrel was a top 10 drug for NVS and still had a couple of years of patent protection when Teva launched at risk. The settlement hit could be significant. This could provide another reason to to tune into TEVA's CC on the 27th.

FL